Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Thoracic 1Plasma cell 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Cytarabine 30fludarabine phosphate 19Specimen Handling 15Cyclophosphamide 15Biopsy 14Peripheral Blood Stem Cell Transplantation 13Busulfan 13Imatinib Mesylate 12Etoposide 12Filgrastim 11Decitabine 11Azacitidine 11Methotrexate 10Idarubicin 10Daunorubicin 10Cyclosporine 9X-Rays 8Tacrolimus 8Antilymphocyte Serum 8tipifarnib 7Vorinostat 7Stem Cell Transplantation 7Radiotherapy 7Magnetic Resonance Spectroscopy 7fludarabine 6decitabine and cedazuridine drug combination 6Phantoms, Imaging 6Topotecan 5Prednisone 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Epinephrine × Myeloid × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡